For the first time since the United States formally withdrew from the World Health Organization in January 2026, federal public health scientists took part—virtually—in the WHO’s semiannual vaccine strain selection meeting. According to reporting by Oregon Public Broadcasting, CDC experts joined counterparts from roughly 50 countries as they reviewed global influenza data to choose strains for the 2026–27 flu vaccine.

The meeting, held this week in Istanbul, is part of the WHO’s Global Influenza Surveillance and Response System, which gathers year‑round samples from more than 130 countries and relies on seven major laboratories worldwide—including the CDC’s facility in Atlanta—to analyze how the virus is evolving. Public health officials told broadcasters that participation from U.S. scientists was limited to virtual attendance, and the Department of Health and Human Services said in a statement that the involvement was technical only and did not alter the federal government’s decision to leave the WHO.

The shift comes after a period in which WHO sample shipments slowed because of the loss of U.S. funding. According to reporting by OPB, WHO officials said earlier this month that international shipments have since resumed, though experts cautioned that the long‑term stability of the system remains uncertain. Former CDC officials interviewed for the report noted that virtual participation may also reduce the influence U.S. researchers once held in shaping vaccine recommendations—an outcome that could alter how closely the final vaccine formulation aligns with viruses circulating in the United States.

For communities in Southwest Washington, the implications are indirect but real. Local vaccination rates, hospital preparedness, and the accuracy of seasonal flu forecasting all depend on global surveillance data. When the United States participates at reduced capacity, the feedback loop between local outbreaks and global strain selection becomes weaker, even if technical expertise continues to flow from CDC laboratories.

Washington state’s public health agencies typically adapt their seasonal flu messaging and resource planning to align with federal guidance and WHO recommendations. Those decisions affect hospital staffing in Longview and Kelso, the availability of vaccine supply in Cowlitz County clinics, and the timing of school‑based flu outreach campaigns. Any reduction in U.S. influence over strain selection could mean that the match between the annual shot and circulating virus is slightly less optimized for American regions, including Southwest Washington.

The WHO is expected to announce its recommended influenza strains on Friday. Manufacturers then begin a months‑long production process to deliver vaccines ahead of the fall season.

Why this matters

Seasonal influenza is one of the few global threats that routinely reaches local emergency rooms. The effectiveness of the annual vaccine—shaped by decisions made at WHO meetings like the one in Istanbul—helps determine how hard flu season hits the Pacific Northwest. For a region where hospital capacity is already strained in winter months, the accuracy of those decisions has direct consequences for patient care.

Sources